Phase II trial of recombinant IFN-α2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer

Journal of Interferon and Cytokine Research

Volumn 18, Issue 4, 1998, Pages 241-245

  Khuri, Fadlo R ^a   Fossella, Frank V ^a   Lee, Jin S ^a   Murphy, William K ^a   Shin, Dong M ^a   Markowitz, Avi B ^a   Glisson, Bonnie S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; MEGESTROL ACETATE; RECOMBINANT ALPHA2A INTERFERON;

ADRENAL METASTASIS; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW METASTASIS; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; LUNG SMALL CELL CANCER; MAINTENANCE THERAPY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

EID: 0031949979     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1998.18.241     Document Type: Article

References (26)

1. TRAVIS, W.D., TRAVIS, L.B., PERCY, C., et al. (1995). Lung cancer incidence and survival by histologic type. Cancer 75, 191-202.
2. CHUTE, C.G., GREENBERG, E.R., BARON, J., et al. (1985). Presenting condition of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer 56, 210-207.
3. CROWN, J.P.A., CHAHINIAN, A.P., JAFFREY, I.S., et al. (1992). Predictors of 5-year survival and curability in small cell lung cancer. Cancer 66, 382-386.
4. JOHNSON, B.E., GRAYSON, J., MAKUCH, R.W., et al. (1990). Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. J. Clin. Oncol. 8, 396-401.
5. DOYLE, A., MARTIN, J.W., FUNA, K., et al. (1985). Markedly decreased expression of class I histocompatibility antigens, protein and RNA in human small cell lung cancer. J. Exp. Med. 161, 1135-1151.
6. GAMBACORTI-PASSERINE, C., RADRIZANNI, M., SARESI, E., et al. (1986). Low or absent expression of class I HLA antigens on small cell lung cancer cells and their resistance to lysis by autologous or allogeneic activated lymphocytes. Proc. Am. Assoc. Cancer Res. 27, 1422 (Abstract).
7. HUSSAIN, A., YEN, R., BORGES, M., et al. (1987). Expression and methylation patterns of class I MHC genes in small cell lung cancer and non-small cell lung cancer. Proc. Am. Assoc. Cancer Res. 28, 349 (abstract).
8. BALL, E.D., SORSENSON, G.D., and PETTENGILL, O.S. (1986). Expression of myeloid and major histocompatibility antigens in small cell carcinoma of the lung cell lines analyzed by cytofluorography: modulation by gamma interferon. Cancer Res. 46, 2335-2339.
9. FUNAK, K., GAZDAR, A.F., MATTSON, K., et al. (1986). Interferon mediated in vivo induction of beta2-microglobulin on small cell lung cancers and midgut carcinoids. Clin. Immunol. Immunopathol. 41, 159-164.
10. MATTSON, K., NIIRANEN, A., PYRHONEN, S., et al. (1989). Low dose natural alpha interferon as maintenance therapy for small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 8, 227 (abstract).
11. JONES, D.H., BLEEHEN, H.M., SLATER, A.J., et al. (1983). Human lymphoblastoid interferon in the treatment of small cell lung cancer. Br. J. Cancer 47, 361-366.
12. MATTSON, K., HOLSTI, L.R., NIIRANEN, A., et al. (1985). Human leukocyte interferon as part of a combined treatment for previously untreated small cell lung cancer. J. Biol. Response Mod. 4, 8-17.
13. OLESEN, B.K., ERNST, P., NISSEN, M.H., et al. (1987). Recombinant interferon A therapy of small cell and squamous cell carcinoma of the lung: a phase II study. Eur. J. Cancer 7, 987-989.
14. WELANDER, C.E., MORGAN, T.M., HOMESLEY, H.D., et al. (1985). Combined recombinant human interferon alpha and cytotoxic agents studied in a human clonogenic assay. Int. J. Cancer 35, 721-729.
15. CARMICHAEL, J., FERGUSSON, R.J., WOLF, C.R., et al. (1986). Augmentation of cytotoxicity of chemotherapy by human alpha interferon in human non-small cell lung cancer xenografts. Cancer Res. 46, 4916-4920.
16. SKLARIN, N.T., CHAHINIAN, A.P., FEUER, E.J., et al. (1988). Augmentation of activity of cisplatin and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice. Cancer Res. 48, 64-67.
17. SMYTH, J., FERGUSSON, R., STEWART, M., et al. (1988). Alpha interferon potentiates cisplatin in patients with non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 7, 201.
18. MILLER, A.B., HOOGSTRATEN, G., and STAQUET, M. (1981). Reporting results of cancer treatment. Cancer 47, 207-214.
19. KAPLAN, E.L., and MEIER, P. (1958). Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457-481.
20. FUKUOKA, M., FURESE, K., SAIJO, N., et al. (1991). Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J. Natl. Cancer Inst. 83, 855-861.
21. ROTH, B.J., JOHNSON, D.H., EINHORN, L.H., et al. (1992). Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J. Clin. Oncol. 10, 282-291.
22. IHDE, D.C., MULSHINE, J.L., KRAMER, B.S., et al. (1994). Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J. Clin. Oncol. 12, 2022-2034.
23. MATTSON, K., NIIRANEN, A., PYRHONEN, S., et al. (1992). Natural interferon alfa as maintenance therapy for small cell lung cancer. Eur. J. Cancer 28A, 1387-1391.
24. KELLY, K., CROWLEY, J.J., BUNN, P.A., et al. (1995). Role of recombinant interferon alfa-2a maintenance in patients with limited stage small cell lung cancer responding to concurrent chemoradiation: a southwest Oncology Group study. J. Clin. Oncol. 13, 2924-2930.
25. JETT, J.R., SU, J.Q., and MAKSYMIUK, A.W. (1994). Phase III trial of recombinant interferon gamma in complete responders with small cell lung cancer. J. Clin. Oncol. 12, 2321-2326.
26. ACKERMAN, M., KIRCHNER, H., and ATZPODIEN, J. (1993). Low dose megestrol acetate can abrogate cachexia in advanced tumor patients receiving systemic interferon-α and/or interleukin-2 based antineoplastic therapy. Anti-Cancer Drugs 4, 585-587.